Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802440 | 0.87 | TRPV4 (0.32) | — | |
| SCHEMBL31371936 | 0.83 | — | — | |
| SCHEMBL18314460 | 0.76 | TRPV4 (0.38) | SQOR | |
| SCHEMBL29490411 | 0.75 | SQOR (0.36) | SQORBRD4 | |
| SCHEMBL22802449 | 0.75 | SQOR (0.36) | SQORBRD4 | |
| SCHEMBL18393568 | 0.74 | CYP19A1 (0.30) | — | |
| SCHEMBL17462545 | 0.73 | — | — | |
| SCHEMBL18314383 | 0.72 | — | — | |
| SCHEMBL22802457 | 0.70 | RIPK1 (0.41) | — | |
| SCHEMBL29490396 | 0.70 | RIPK1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025036382-A1 | SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海复宏汉霖生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2025007873-A1 | KAT6 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2025-01-09 | — | — | WO | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114364672-A | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2022-04-15 | — | — | CN | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | SQOR 14/4885BRD4 92/4885TDP1 3530/4885 |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | SQOR 17/4885BRD4 91/4885TDP1 3266/4885 |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | SQOR 14/4885BRD4 92/4885TDP1 3530/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | SQOR 1304/4885BRD4 131/4885TDP1 1795/4885 |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | SQOR 14/4885BRD4 92/4885TDP1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.